Nepicastat oral

Drug Profile

Nepicastat oral

Alternative Names: DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Biotie Therapies Corp.
  • Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cocaine abuse; Parkinson's disease; Post-traumatic stress disorders

Most Recent Events

  • 27 May 2014 The National Institute on Drug Abuse & Biotie complete enrolment in a phase II trial for Cocaine abuse in USA (NCT01704196)
  • 22 May 2014 Phase-II development is ongoing in USA
  • 13 May 2013 Biotie Therapies initiates enrolment in a phase II trial for Cocaine abuse in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top